Perrigo Co. PLC's Ratings Affirmed, Removed From CreditWatch; Outlook Negative - S&P Global Ratings’ Credit Research

Perrigo Co. PLC's Ratings Affirmed, Removed From CreditWatch; Outlook Negative

Perrigo Co. PLC's Ratings Affirmed, Removed From CreditWatch; Outlook Negative - S&P Global Ratings’ Credit Research
Perrigo Co. PLC's Ratings Affirmed, Removed From CreditWatch; Outlook Negative
Published Nov 13, 2015
4 pages (1436 words) — Published Nov 13, 2015
Price US$ 150.00  |  Buy this Report Now

About This Report

  
Abstract:

Less than 50% of Ireland-based Perrigo Co. plc's (Perrigo) stockholders have agreed to tender their shares to Mylan N.V. (Mylan), meaning the hostile takeover attempt of Perrigo has failed. We assume Perrigo will remain an independent company in the consolidating global health care industry. We are affirming all of our ratings on Perrigo, including our 'BBB' corporate credit rating, removing them from CreditWatch, where they were placed with negative implication on April 9, 2015, and assigning a negative outlook. The negative outlook reflects the downside risk for the company's financial policy to become more aggressive than we currently assume, which could include higher than expected acquisition activity or share repurchases, resulting in debt to EBITDA remaining above 3x over our

  
Brief Excerpt:

...+ Less than 50% of Ireland-based Perrigo Co. plc's (Perrigo) stockholders have agreed to tender their shares to Mylan N.V. (Mylan), meaning the hostile takeover attempt of Perrigo has failed. + We assume Perrigo will remain an independent company in the consolidating global health care industry. + We are affirming all of our ratings on Perrigo, including our '###' corporate credit rating, removing them from CreditWatch, where they were placed with negative implication on April 9, 2015, and assigning a negative outlook. + The negative outlook reflects the downside risk for the company's financial policy to become more aggressive than we currently assume, which could include higher than expected acquisition activity or share repurchases, resulting in debt to EBITDA remaining above 3x over our forecast horizon. It is also possible that new suitors for Perrigo could emerge. CHICAGO (Standard & Poor's) Nov. 13, 2015--Standard & Poor's Ratings Services said today that it affirmed all of its ratings...

  
Report Type:

Ratings Action

Issuer
GICS
Pharmaceuticals (35202010)
Sector
Global Issuers
Country
Region
Europe, Middle East, Africa
Format:
PDF Adobe Acrobat
Buy Now

S&P Global Ratings’ Credit Research—S&P Global Ratings’ credit research provides analysis on issuers and debt obligations of corporations, states and municipalities, financial institutions, insurance companies and sovereign governments. S&P Global Ratings also offers insight into the credit risk of structured finance deals, providing an independent view of credit risk associated with a growing array of debt-securitized instruments.

About the Author


Cite this Report

  
MLA:
S&P Global Ratings’ Credit Research. "Perrigo Co. PLC's Ratings Affirmed, Removed From CreditWatch; Outlook Negative" Nov 13, 2015. Alacra Store. May 22, 2025. <http://www.alacrastore.com/s-and-p-credit-research/Perrigo-Co-PLC-s-Ratings-Affirmed-Removed-From-CreditWatch-Outlook-Negative-1480638>
  
APA:
S&P Global Ratings’ Credit Research. (). Perrigo Co. PLC's Ratings Affirmed, Removed From CreditWatch; Outlook Negative Nov 13, 2015. New York, NY: Alacra Store. Retrieved May 22, 2025 from <http://www.alacrastore.com/s-and-p-credit-research/Perrigo-Co-PLC-s-Ratings-Affirmed-Removed-From-CreditWatch-Outlook-Negative-1480638>
  
US$ 150.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.